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Proteasome system dysregulation and treatment resistance
mechanisms in major depressive disorder
A Minelli1,6, C Magri1,6, A Barbon1, C Bonvicini2, M Segala3, C Congiu1, S Bignotti4, E Milanesi2,5, L Trabucchi3, N Cattane2,
M Bortolomasi3 and M Gennarelli1,2
Several studies have demonstrated that allelic variants related to inflammation and the immune system may increase the risk for
major depressive disorder (MDD) and reduce patient responsiveness to antidepressant treatment. Proteasomes are fundamental
complexes that contribute to the regulation of T-cell function. Only one study has shown a putative role of proteasomal PSMA7,
PSMD9 and PSMD13 genes in the susceptibility to an antidepressant response, and sparse data are available regarding the potential
alterations in proteasome expression in psychiatric disorders such as MDD. The aim of this study was to clarify the role of these
genes in the mechanisms underlying the response/resistance to MDD treatment. We performed a case-control association study on
621 MDD patients, of whom 390 were classified as treatment-resistant depression (TRD), and we collected peripheral blood cells
and fibroblasts for mRNA expression analyses. The analyses showed that subjects carrying the homozygous GG genotype of
PSMD13 rs3817629 had a twofold greater risk of developing TRD and exhibited a lower PSMD13 mRNA level in fibroblasts than
subjects carrying the A allele. In addition, we found a positive association between PSMD9 rs1043307 and the presence of anxiety
disorders in comorbidity with MDD, although this result was not significant following correction for multiple comparisons. In
conclusion, by confirming the involvement of PSMD13 in the MDD treatment response, our data corroborate the hypothesis that
the dysregulation of the complex responsible for the degradation of intracellular proteins and potentially controlling autoimmunity-
and immune tolerance–related processes may be involved in several phenotypes, including the TRD.
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INTRODUCTION
Major depressive disorder (MDD) is a major health problem
associated with gradual and often incomplete recovery and with
significant limitations in functioning and well-being. Unfortu-
nately, several studies have shown that only about one-third of
patients experience full remission after first-choice treatment,
and that for many patients achieving remission requires repeated
trials of sufficiently dosed antidepressant medication.1,2 In
addition, 15–30% of MDD patients are classified as having
treatment-resistant depression (TRD).3,4
Carvalho et al.5,6 reported that increased activation of the
inflammatory system is concordant with hyperactivity of the
hypothalamic–pituitary–adrenal axis and with impaired glucocor-
ticoid receptor (GR) sensitivity in TRD patients. These findings
were corroborated by genetics studies indicating that functional
allelic variants in the interleukin (IL)-1beta (IL-1b), tumor necrosis
factor-α and C-reactive protein genes, as well as genetic variations
affecting T-cell function, may increase the risk for depression.
Moreover, single nucleotide polymorphisms (SNPs) in the IL-1b,
IL-6 and IL-11 genes and in those regulating T-cell function may
be associated with reduced responsiveness to antidepressant
therapy.7
Although the aforementioned ILs and other factors have been
extensively studied in MDD and in the response to its treatment,
few studies of T-cell function are available to date.
Fundamental complexes that contribute to regulate T-cell
function are proteasomes. In fact, proteasomes are the major
multi-catalytic enzyme complexes involved in the intracellular
degradation of ubiquitinated proteins and in the production of
small protein fragments that can be used by major histocompati-
bility complex class I to present antigens to the immune system.
Protein degradation is fundamental for many important biological
functions, such as immune surveillance, cell cycle progression,
apoptosis and synaptic reorganization; therefore, the disruption or
alteration of this mechanism due to genetic variants can have a
relevant impact on several diseases.8
Based on genetic studies, the ubiquitin–proteasome system has
been identified as a canonical pathway that is associated with
neuropsychiatric disorders such as Alzheimer disease,9 psychosis10
and bipolar disorder.11–13 In particular, two studies showed that
several proteasome 26S subunits are significantly downregulated
in schizophrenia,14,15 and Bousman et al.11 suggested that the
dysregulation of the ubiquitin–proteasome system may partially
determine the manifestation and the severity of psychotic
symptoms in schizophrenia and mood disorders.
Only one study has shown a putative role of proteasomal
subunit genes in the susceptibility to MDD and the antidepressant
response.16 The authors observed that the proteasome subunit β4
(PSMD4) gene is involved in etiopathogenesis of MDD, although
this result was not replicated in the largest genome-wide
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association study on MDD.17 Alternatively, Wong et al.16 found
significant associations of the treatment response with the 26S
proteasome non-ATPase subunit 9 (PSMD9), proteasome alpha
type 7 subunit (PSMA7) and PSMD13 genes. Recently, the PSMD9
gene has been found to be associated with generalized anxiety
disorder.18
Finally, although data are available regarding the proteasome
expression levels in human peripheral tissues in MDD patients,19,20
to the best of our knowledge, no data have been reported
concerning the relationship between the expression pattern of the
ubiquitin–proteasome system and the antidepressant treatment
response. Peripheral blood cells (PBCs) are frequently used to
identify depression biomarkers;21 however, recent evidence has
indicated that fibroblasts represent a promising model for
studying several processes related to MDD22 because many
possible confounding factors that are often associated with
patient PBCs, such as diet, lifestyle, smoking status and drug
treatment, may be virtually eliminated after several cycles of cell
division.23
Based on the above findings, to better understand the role of
proteasome genes in the mechanisms underlying the MDD
treatment response, we (1) investigated the potential roles of
three genes (PSMA7, PSMD9 and PSMD13) previously found to be
associated with drug responses,16 (2) performed single-gene
re-analysis on the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) data set and (3) analyzed the expression
profiles of PBCs and fibroblasts.
MATERIALS AND METHODS
Sample
About 621 MDD patients with at least moderate to severe depression, who
met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)
classification system criteria were voluntarily enrolled in the study. All of
them had been referred to the Villa S. Chiara Psychiatric Hospital in Verona
or to the Psychiatry Rehabilitation Unit of IRCCS Centro Fatebenefratelli ‘S.
Giovanni di Dio’ in Brescia.
Diagnosis of unipolar depression was confirmed using the Structured
Clinical Interview for DSM-IV Axis I Disorders (SCID-I) diagnostic scale. The
exclusion criteria were as follows: (a) mental retardation or cognitive
disorder; (b) a lifetime history of schizophrenic, schizoaffective or bipolar
disorder; (c) personality disorder, substance abuse, alcohol abuse or
dependency, obsessive-compulsive disorder or post-traumatic stress
disorder as the primary diagnosis; and (d) comorbidity with an eating
disorder.
About 147 patients (23.7%) showed psychotic symptoms; 258 (41.5%)
showed current comorbidity in Axis I (generalized anxiety disorder, panic
attacks or anxiety disorder not otherwise specified), 139 (22.4%) showed
symptoms of Axis II disorders (paranoid, dependent, obsessive-compulsive
or histrionic personality disorder) and 24 (3.9%) alcohol abuse, as a
secondary diagnosis (the total number exceeded the number of subjects
due to the presence of comorbidities).
About 390 subjects were classified as TRD patients (Group 1: TRD).
Treatment resistance to antidepressants was defined as the failure to
respond to two or more adequate trials of two or more different classes of
antidepressants and to an adequate trial of a tricyclic antidepressant drug;
such patients were classified as Stage III according to the Thase and Rush
staging method.24
The second group was composed of 231 MDD patients experiencing a
depressive episode who responded to their current treatment (Group 2:
non-TRD).
The control sample consisted of 467 unrelated healthy volunteers who
were screened for DSM-IV Axis I disorders by expert psychologists using
the Mini-International Neuropsychiatric Interview (M.I.N.I.).25 Only healthy
volunteers without a history of drug or alcohol abuse or dependence and
without a personal or first-degree family history of psychiatric disorders
were enrolled in the study. Furthermore, subjects who obtained a score
o27/30 on the Mini Mental State Examination (M.M.S.E.)26 were excluded
from the study.
All socio-demographic and clinical characteristics for all groups are
shown in Table 1.
We performed transcriptional analyses on 59 PBCs (from 37 MDD
patients, including 20 non-TRD and 17 TRD patients, and 22 controls) and
48 fibroblasts samples (from 27 MDD patients, including 17 non-TRD and
10 TRD patients, and 21 controls). The socio-demographic and clinical
features for both tissue samples are shown in Table 2.
Only for transcriptional analyses, we used the following additional
exclusion criteria: (1) age470 years old, because fibroblasts have a shorter
life span in culture; (2) presence of metabolic disorders (for example,
diabetes); and (3) presence of specific skin diseases (for example, skin
cancer or psoriasis).
Both patients and controls were Caucasians of Italian descent for at least
two generations, residing in north Italy and unrelated to other participants.
The study was approved by the Local Ethics Committees (CEIOC IRCCS
Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia N: 50/2008 and
Ethics Committee of the province of Verona N: 4997/09.11.01), and written
informed consent was obtained.
Genotyping
PSMD13 rs3817629, PSMD9 rs1043307 and PSMA7 rs2057168 were
genotyped using the BeadXpress System and the VeraCode Assay
according to the manufacturer's instructions (http://www.illumina.com).
The raw BeadXpress data were processed using the Illumina BeadStudio
software suite (genotyping module 3.3.7; San Diego, CA, USA), producing
report files containing normalized intensity data and SNP genotypes.
Table 1. Demographic and clinical characteristics of both the control and MDD patient groups, as well as the non-TRD and TRD patient subgroups
Characteristics Controls (N= 467) MDD (N= 621) P-value
Age (years), mean (s.d.) 46.9 (16.3) 56.2 (13.7) o0.001
Gender (F), n (%) 260 (55.7) 422 (68.0) o0.001
Education (years), mean (s.d.) 12.7 (4.7) 9.2 (4.0) o0.001
TRD (N= 390) Non-TRD (N= 231)
Age (years), mean (s.d.) 56.8 (13.4) 55.2 (14.1) 0.16
Gender (F), n (%) 260 (66.7) 162 (70.1) 0.37
Education (years), mean (s.d.) 8.9 (3.9) 9.8 (4.1) 0.007
% Of recurrent MDD 90.5 70.1 o0.001
% Of severe vs moderate MDD 87.9 45.0 o0.001
% Psychotic symptoms 35.6 3.5 o0.001
% Comorbidity with personality disorders 26.7 15.2 0.001
% Comorbidity with anxiety disorders 43.6 38.1 0.18
% Comorbidity with alcohol abuse 3.3 4.8 0.37
Abbreviations: F, female; MDD, major depressive disorder; PBC, peripheral blood cell; TRD, treatment-resistant depression.
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The genotyping of PSMD13 rs3817629 and PSMD9 rs1043307 was
repeated via the SNaPshot assay as a quality control. All details regarding
the SNaPshot assay are available on request.
LD analysis
For the intronic SNP PSMD13 rs3817629, that was positively associated with
response, we tested for linkage disequilibrium (LD) with other variants
selected for their putative effects on protein function. Using the 1000
Genome database data, we computed the LD coefficient (r2) between the
PSMD13 rs3817629 and all SNPs mapping inside PSMD13 gene and 10 kb
downstream and upstream the gene. Then we selected those displaying
r240.8. For coding variants, functional prediction was performed using
the Variant Annotation Integrator (http://genome.ucsc.edu/index.html),
and for noncoding variants, functional prediction was performed using the
Regulome database (http://regulomedb.org/).27
STAR*D data sets replication study
We evaluated genetic data from data set 2 and 3 of the STAR*D study28
(https://www.nimhgenetics.org/) – distribution 3.02, selecting only patients
defined as ‘White’; we categorized these patients into the non-TRD and
TRD groups. We defined any MDD patient who did not respond to two or
more trials of different classes of antidepressants as TRD. We excluded
subjects who responded to citalopram at Level 1 of the study from the
non-TRD group to avoid placebo effects.29,30 The population consisted of
259 non-TRD and 186 TRD patients. Logistic regression analyses were
performed to evaluate differences in the genotype frequency distribution
between the two groups. To correct for ethnic heterogeneity, we
performed principal component analysis, and we used the first three
components as covariates in the regression analyses. None of the analyzed
SNPs was directly genotyped in the STAR*D cohort. Therefore, for the SNP
PSMA7 rs2057168, the association was indirectly tested by analyzing
the SNP rs1535669, which displayed high LD (r2 = 0.95) with rs2057168
in the European population accordingly to the NetAffx database of
Affymetrix (http://www.affymetrix.com). For PSMD13 rs3817629 and PSMD9
rs1043307, because no SNPs displaying LD were available in the
STARD data set, the association was tested using dosage data of the
imputed genotypes. The SNPs within chromosomal regions (Hg19)
chr11:236,808–252,984 and chr20:122,326,812–122,386,604 were imputed
using Beagle software31 and using the 1000 Genome database.
All logistic regression analyses were performed using Plink software
(v.1.9).32,33
Cell culture and RNA isolation
Skin biopsies (3 mm2) were collected under local anesthesia from the
scapular region under aseptic conditions and were immediately immersed
in saline solution (phosphate-buffered saline). All primary cultures were
grown in Eagle’s minimum essential medium (Invitrogen-Life Technologies,
Carlsbad, CA, USA) supplemented with fetal bovine serum (10%), penicillin
(100 Uml− 1), streptomycin (100 μgml− 1), non-essential amino acids
(1% v/v) and glutamine (1% v/v) under optimal conditions (37 °C and
5% CO2). The medium was replaced every 3 days. When the fibroblasts
reached confluence, the cells were subcultured into larger tissue culture
dishes or were frozen in 20% foetal bovine serum and 10% DMSO. All
fibroblasts were cultured until the fifth passage. Fibroblast cell cultures
were screened for mycoplasma infection and mycoplasma removal agents
were used to avoid and prevent the risk of contamination.
RNA was extracted from fibroblasts using the NucleoSpin kit
(Carlo Erba Reagenti, Milan, Italy) according to the manufacturer’s
instructions.
Blood samples were collected between 0800 and 0900 hours after an
overnight fast via venepuncture using PaxGene Tubes (Qiagen, Crawley,
UK). RNA isolation was performed using the PaxGene Blood RNA Kit
(Qiagen) according to the manufacturer’s instructions.
One microgram of total RNA was used for complementary DNA
synthesis using random hexamer primers (Invitrogen-Life Technologies)
and Superscript II Reverse Transcriptase (Invitrogen-Life Technologies)
according to the manufacturer’s instructions.
Real-time PCR analyses
For those genes in which a positive genotype association was found
(PSMD13 and PSMD9), the mRNA expression level was evaluated in both
fibroblasts and PBCs.
The transcriptional expression levels were determined with TaqMan
assays (Applied Biosystems, Foster City, CA, USA) performed on a
StepOnePlus instrument (Applied Biosystems) according to the manufac-
turer’s protocol.
In a pilot study in fibroblasts, we found that GAPDH is among the most
stable reference genes in this tissue (data not shown). Moreover, GAPDH
has been already used as a reference in MDD studies using fibroblasts and
PBCs.34–36 Therefore, the relative expression levels of the target genes in
the patient groups were calculated according to the comparative Ct
method (−ΔΔCt method)37 using GAPDH as the reference gene. Each
determination was repeated in duplicate.
Table 2. Demographic and clinical characteristics of both the control and MDD patient groups, as well as the TRD and non-TRD subgroups, from
which fibroblast and PBC samples were collected
Fibroblasts PBCs
Characteristics Controls (N= 21) MDD (N=27) P-value Controls (N= 22) MDD (N=37) P-value
Age (years), mean (s.d.) 46.6 (11.9) 51.2 (12.8) 0.66 32.1 (5.1) 49.9 (12.4) o0.001
Gender (% F) 47.6 66.7 0.18 50.0 73.0 0.08
Education (years), mean (s.d.) 13.7 (5.8) 8.6 (3.5) 0.001 16.8 (4.1) 10.6 (4.6) o0.001
BMI 24.8 (2.5) 26.1 (6.0) 0.41 23.3 (2.6) 25.3 (4.3) 0.07
% Smokers 4.8 40.9 0.005 22.7 50.0 0.04
TRD (N= 10) Non-TRD (N=17) TRD (N= 17) Non-TRD (N= 20)
Age (years), mean (s.d.) 48.6 (9.7) 52.7 (14.4) 0.43 52.3 (11.9) 47.7 (12.7) 0.25
Gender (% F) 64.7 70.0 0.78 64.7 80.0 0.30
Education (years), mean (s.d.) 8.7 (4.2) 8.6 (3.2) 0.94 10.8 (5.9) 10.4 (3.2) 0.78
BMI 28.5 (6.1) 25.2 (6.0) 0.36 25.2 (3.6) 25.5 (5.0) 0.85
% Smokers 33.3 46.2 0.55 35.3 64.7 0.09
% Of recurrent MDD 100.0 82.4 0.16 100.0 45.0 o0.001
% Of severe vs moderate MDD 50.0 47.1 0.88 88.2 45.0 0.006
% Psychotic symptoms 0.0 5.9 0.43 70.6 0.0 o0.001
% Comorbidity with personality disorders 40.0 35.3 0.81 76.5 25.0 0.002
% Comorbidity with anxiety disorders 40.0 29.4 0.57 64.7 25.0 0.02
% Comorbidity with alcohol abuse 20.0 0.0 0.06 5.9 0.0 0.27
Abbreviations: BMI, body mass index; F, female; MDD, major depressive disorder; PBC, peripheral blood cell; TRD, treatment-resistant depression.
Proteasome system in treatment-resistant depression
A Minelli et al
3
Translational Psychiatry (2015), 1 – 8
Statistical analyses
Analysis of variance was used to detect possible differences in age
and education between controls and MDD, as well as between TRD and
non-TRD. χ2-tests were used to detect differences in demographic and
clinical variables between the groups (Table 1). The differences in
genotype frequency distribution for the three SNPs between MDD and
controls were tested using a logistic regression analysis. Since the two
groups differed in terms of gender, age and education (see Table 1) these
variables were considered as covariates in the model. The same analyses
were performed to test differences in genotype frequency distribution
between TRD and non-TRD, and education (Table 1) was considered as
covariate in the model. Moreover, we performed secondary analyses by
logistic regression to investigate the putative influences of these three
SNPs on comorbidity with anxiety disorders and the presence of psychotic
symptoms. The additive, dominant and recessive genotype models were
tested. All P-values were adjusted applying Bonferroni correction for all
comparisons (N= 36). Odds ratios and corresponding 95% confidence
intervals (CIs) were used to quantify the association. All the genotype
analyses were performed with Plink (v. 1.9) software.
According to G*Power Calculator software38,39 in our cohorts of TRD e
non-TRD patients, we have a power greater than 95% (for αo0.0014) of
detecting the same allele differences (odds ratioso0.44), reported in the
study by Wong et al.16 between responder and nonresponder.
The Kruskal–Wallis and Mann–Whitney U non-parametric tests were
used to evaluate differences in PSMD13 and PSMD9 mRNA levels between
MDD and controls, as well as between TRD and non-TRD, and to evaluate
the association between the expression levels of the same genes with the
relative polymorphisms. Pearson's coefficient was used to evaluate
bivariate correlations between mRNA expression levels and the
socio-demographic and clinical variables reported in Table 2.
Parametric and non-parametric tests were used meeting relative
assumptions (for example, distribution, sample size).
All statistical analyses were conducted using SPSS version 17.0 (SPSS,
Chicago, IL, USA).
RESULTS
Genetic analysis results for our sample
As reported in Table 3, none of the analyzed SNPs showed a
significantly different genotype frequency distribution between
the controls and the patients using the additive model. The
identical results were observed using the dominant and recessive
models (data not reported).
When the patients were stratified into the TRD and non-TRD
groups, differences in the genotype distribution of PSMD13
rs3817629 was observed (P= 0.004); GG homozygotes were more
frequent in TRD patient group (56%, P= 0.00045, OR= 1.75, 95%
CI: 1.26–2.45) (Table 4). This difference remained significant after
adjustment for multiple comparisons (P = 0.016).













CTRL 296 (0.64) 148 (0.32) 21 (0.04) 0.59 0.48




CTRL 207 (0.44) 219 (0.47) 40 (0.09) 0.23 0.68




CTRL 224 (0.48) 202 (0.44) 37 (0.08) 0.41 Not genotyped
MDD 311 (0.51) 261 (0.42) 42 (0.07)
Abbreviations: CTRL, control; MDD, major depressive disorder; PGC, Psychiatric Genomics Consortium; SNP, single nucleotide polymorphism. aGender, age and
education were considered as covariates in the model.
















Non-TRD 143 (0.62) 77 (0.33) 10 (0.04) 0.35 0.22 0.79




Non-TRD 107 (0.46) 101 (0.44) 21 (0.09) 0.50 0.33 0.90




Non-TRD 94 (0.42) 115 (0.51) 16 (0.07) 0.004 0.0005 0.87
TRD 217 (0.56) 146 (0.38) 26 (0.07)
Abbreviations: SNP, single nucleotide polymorphism; TRD, treatment-resistant depression. aEducation was considered as a covariate in the model. Bold
numbers indicate significant P-values (o0.05).
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The Regulome database reported that PSMD13 rs3817629 is an
intronic SNP displaying minimal evidence of affecting transcrip-
tion factor-binding sites (score: 4). LD analysis of the genotypic
data from the 1000 Genome database revealed that PSMD13
rs3817629 is in high LD with 40 SNPs located inside or close to
PSMD13 gene, 6 of which are missense variants mapping to the
first or second exon of the PSMD13 gene and predicted as benign
using Polyphen (http://genetics.bwh.harvard.edu/pph/) (Supple-
mentary Figure 1S). Moreover, rs10902110 and rs10794302, were
identified as intronic variants expected to affect the binding of
transcription factors (Regulome score: 2b). Chromatin immuno-
precipitation sequencing (chip-seq) analysis indicated that
rs10902110, which maps to the first intron of the PSMD13 gene,
is located in an open chromatin locus that binds to RNA
polymerase II and other transcription factors such as CREBBP,
RFX3, MYC, SP1, GABPA and ELF140–42 (ENCODE project).
Alternatively, rs10794302 maps to the first intron of the SIRT3
gene at a locus predicted to have an open chromatin structure
and a transcription factor-binding motif. Chip-seq analysis
suggested that the GR (NR3C1) binds to this region (ENCODE
project). Significant associations were detected between the
presence of anxiety disorders in comorbidity with MDD and
PSMD9 rs1043307. The genotype frequency distribution of this
SNP was significantly different between MDD patients with and
without anxiety disorders according to the additive model
(P = 0.035). In particular, subjects carrying the AA or AG genotype
exhibited a 1.76-fold (95% CI 0.98–3.18) and 1.38-fold (95% CI
0.76–2.51) increased risk of anxiety comorbidity relative to
subjects carrying the homozygous GG genotype, respectively.
However, this result did not remain significant after adjustment for
multiple comparisons.
Replication of the genotypic data in the STAR*D cohort
To confirm our results, we replicated the genotypic analyses in
subgroups of STAR*D patients. As shown in Table 5, none of the
analyzed SNPs showed a significantly different genotype distribu-
tion between the TRD and non-TRD groups. We also tested the
possible association between PSMD9 and anxiety in 118 patients
with and 972 patients without comorbid anxiety disorder. No
difference in the rs1043307 genotype frequency distribution was
observed between these two groups (P= 0.74).
mRNA expression analysis on fibroblasts
The analyses of the expression levels of PSMD13 mRNA in
fibroblasts from MDD subjects and controls revealed no significant
differences between the two groups, as well as comparing TRD
and non-TRD patients. Furthermore, no significant association
with any examined socio-demographic or clinical variables was
detected (data not shown). However, we found a trend toward a
correlation between the PSMD13 genotype and its mRNA levels
(H= 5.10; 2 degree of freedom, P= 0.08). In particular, the
homozygous GG carriers displayed lower expression levels than
the A allele carriers (z =− 2.20; P = 0.03) (Figure 1a). However, after
stratifying the subjects into the control and MDD patient groups,
this downregulation was observed only in MDD patients
(z=− 2.40; P = 0.02) (Figure 1b), whereas in control sample this
association was not obtained (11A allele carriers, 9 GG; z=− 0.57;
P= 0.60) (Figure 1c).
Regarding the expression of PSMD9, the analyses did not reveal
any significant differences in its mRNA levels (data not shown).
mRNA expression analysis on PBCs
The analyses of PSMD13 mRNA levels in PBCs did not show any
differences, both when we compared MDD and controls, as well
as TRD and non-TRD patients. No association, neither with
PSMD13 polymorphism nor with any socio-demographic or clinical
variables, was detected.
As concerned PSMD9, we observed a significant downregulation
in MDD patients compared with healthy controls (z=− 3.75;
P= 1.80 × 10− 4) (Figure 2a). Pairwise comparisons indicated high
differences between non-TRD patients group and both controls
(z=− 4.51; P= 6.54 × 10− 6) and TRD patients (z=− 3.38; P= 0.001),
whereas, no significant difference was observed between the TRD
patients and the healthy subjects (z=− 1.70; P= 0.09) (Figure 2b).
Our data also revealed significant correlations between PSMD9
mRNA levels with the presence of psychotic symptoms (r= 0.43;
P= 0.008), comorbidity with anxiety disorders (r= 0.40; P= 0.01)
and smoke (r=− 0.39; P= 0.003). No significant correlation
between mRNA levels with PSMD9 rs1043307 SNP was observed.
Table 5. Logistic regression results for the genotype frequency
distributions between the non-TRD and TRD patients in the STAR*D
cohort
Gene SNP tested P-value additive
modela,b
Note
PSMA7 rs1535669 0.76 LD r2= 0.95 with
rs2057168
PSMD9 rs1043307 0.30 Imputed with r2= 0.89
PSMD13 rs3817629 0.98 Imputed with r2= 0.94
Abbreviations: LD, linkage disequilibrium; PCA, principal component
analysis; SNP, single nucleotide polymorphism. aThe first three PCAs were
considered as covariates in the analysis. bFor the imputed SNPs, the
B allelic dosage was used as independent variables in the regression.
Figure 1. Relative expression mRNA levels of PSMD13 rs3817629. Box-plots showing the median, quartiles and extreme values of relative
expression of PSMD13 rs3817629 A allele carriers with respect to GG subjects. The bold lines represent median values, the box boundaries
mark the 25th and 75th percentiles of each distribution, respectively. Whiskers, above and below the hinges, mark the largest and smallest
observed values. (a) the analysis was performed in all subjects; (b) only in MDD group; (c) only in control group. '*' Indicates significant
difference (P-valueo0.05) computed by the Mann–Whitney U non-parametric test. MDD, major depressive disorder.
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DISCUSSION
In the present study, we found an association between the
PSMD13 rs3817629 G allele and TRD. In particular, homozygotic
GG have about a twofold higher risk of developing MDD
treatment resistance than A allele carriers. Our result supports
the original observation of Wong et al.,16 who found that the A
allele is associated with the antidepressant treatment response in
a cohort of depressed patients.
LD analysis revealed that although rs3817629 does not appear
to affect a binding site, it is in high LD with two SNPs, rs10794302
and rs10902110, which likely affect binding sites according to the
Regulome database. In particular, Chip-seq analyses showed that
rs10794302 maps to a locus corresponding to a GR-binding site.
This result is intriguing because it has been observed that
antidepressants exert their clinical effects via the modulation of
the GR.43
Moreover, our expression analysis revealed that the homozygous
GG genotype was associated with reduced transcription of
PSMD13 in MDD fibroblasts. This result suggests that rs3817629
is an expression quantitative trait locus in this tissue. Our finding is
corroborated by a recent study that investigated the genetic
variability in the regulation of gene expression in 10 regions of the
human brain.44 The authors found that rs3817629 is a
cis-expression quantitative trait locus in different areas of the
brain and that this SNP is associated with the PSMD13 transcriptional
expression level (t3315549) in the entire brain (http://www.
braineac.org/). Specifically, this result was primarily due to the
differential expression observed in eight brain regions: the
cerebellar cortex, the hippocampus, the inferior olivary nucleus,
the occipital cortex, the putamen, the temporal cortex, the
thalamus and the intralobular white matter. In all of these tissues,
as in our fibroblasts, the homozygous GG genotype was
associated with lower PSMD13 expression providing further
evidence that fibroblasts serve as a good peripheral model for
the study of biomarkers of the central nervous system.22,45,46
This transcriptional finding combined with our genetic main
result, that the homozygous GG subjects have about a twofold
higher risk of developing MDD treatment resistance, might
suggest that this SNP may represent a risk factor for TRD due to
alteration of PSMD13 transcription. Unfortunately, the small
sample size of our TRD and non-TRD groups for expression
analysis, do not allow us to test differences in the mRNA levels
between these two groups as concern the GG genotype.
Under inflammatory conditions mediated by IFN-γ, the activa-
tion of the mTOR pathway enhances protein translation and
induces protein-damaging oxygen radical production; these
events contribute to an increase in the synthesis of proteins that
fail to fold correctly, referred to as defective ribosomal products
and in proteasomal activity.47,48 We suggest that subjects carrying
the GG genotype and, thus, a low expression level of PSMD13 may
respond less effectively to conditions of augmented need for
defective ribosomal product degradation, such as those caused by
stress or an inflammatory response, which are observed in MDD.
Therefore, such conditions could lead to more severe phenotypes
and to worse drug treatment responses in MDD patients.
Our negative pharmacogenetic results for PSMD9 did not
confirm the previous finding reported by Wong et al.;16 however,
a recent study has shown that the PSMD9missense SNP rs1043307
co-segregates with generalized anxiety disorder in type-2 diabetes
families.18 Interestingly, we found a positive association between
this SNP and the presence of anxiety disorders in comorbidity with
MDD. Although our result did not remain significant after
correction for multiple comparisons, taken together these data
support the putative role of PSMD9 as a risk factor for anxiety
phenotypes.
Anxiety disorders co-occur in the same individual, either
simultaneously or sequentially, with MDD (in ~ 40–50% of
patients), and it has been widely demonstrated that anxiety
impairs depression remission.49 Furthermore, several pieces of
evidence led to the hypothesis that these two phenotypes have
partially shared genetic bases.49–52 This observation suggests that
PSMD9 variants may be indirectly implicated in the response
through an involvement in one of the most important negative
predictor of response like anxiety.
The likely involvement of PSMD9 in MDD phenotypes was also
suggested by our transcriptional data. In fact, mRNA expression
analysis of PBCs revealed that PSMD9 is significantly
downregulated in MDD patients, specifically non-TRD patients,
compared with controls. This result is in agreement with those
observed in one of the largest genome-wide gene expression
study in MDD.19 The results of single-gene association with MDD
status, available on request from the National Institute of Mental
Health (NIMH) Center for Collaborative Genomic Studies on
Mental Disorders, (https://www.nimhgenetics.org/access_data_bio
material.php), indicated that the mRNA expression levels of PSMD9
gene were decreased in whole blood of MDD patients (nominal
P-value = 0.02).
However, our PBCs transcriptional levels are strongly associated
to the presence of psychotic symptoms, the comorbidity with
anxiety disorders and smoke. Thus, it is difficult to clarify if rather
than being the cause of MDD, the alterations of PSMD9 could
probably be a consequence of the disease, since it is well-known
that a depressive state has an adverse influence on lifestyle.
For both genes (PSMD13 and PSMD9), we observed a
discrepancy between PBCs and fibroblasts expression results. This
could be explained by biases due to confounding factors that
probably affect PBCs findings. Indeed, fibroblasts are maintained
Figure 2. Relative expression mRNA levels of PSMD9 rs1043307. Box-plots showing the median, quartiles and extreme values of relative
expression of PSMD9 rs1043307 in (a) MDD patients and controls; (b) in healthy subjects, TRD and non-TRD. The bold lines represent median
values, the box boundaries mark the 25th and 75th percentiles of each distribution, respectively. Whiskers, above and below the hinges, mark
the largest and smallest observed values, respectively. '**' Indicates significant difference (P-valueo0.01), whereas '***' indicates a P-value
o0.001, computed by the Kruskal–Wallis and Mann–Whitney U non-parametric tests.
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in cultures in a controlled, reproducible environment, and after
several rounds of cell division they are minimally affected by
confounding factors (for example, lifestyle or medication use) to
which, in contrast, PBCs are exposed.22,35,46,53,54
The genetic analyses performed on the STAR*D cohort were not
consistent with the results from our cohort or from Wong et al.16
These contrasting results could be explained by different reasons:
(1) neither SNP was directly genotyped in the STAR*D cohort, but,
albeit with high confidence, they were imputed, and therefore, the
analysis was performed on predicted genotypes rather than on
actual genotypes; (2) our samples and those of Wong et al.16 and
the STAR*D cohort differed with respect to certain clinical
characteristics. For instance, the STAR*D study included only
outpatients with non-psychotic MDD, whereas both our sample
than the Wong et al.16 one include MDD patients with psychotic
symptoms. In addition, only ~ 11% of the patients in the selected
STAR*D cohort presented anxiety disorders in comorbidity,
whereas this percentage was 40% in our sample and in the study
by Wong et al.16,55 the patients showed an high severity of
anxiety. As mentioned above, anxiety is a relevant negative
predictor of the treatment response; moreover, in our cohort and
in the STAR*D cohort we stratified in TRD and non-TRD patients,
whereas Wong et al.16 stratified in responders and non-responders
to desipramine or fluoxetine; and (3) the ethnicity in the STAR*D
cohort is more heterogeneous than in the cohort of Wong et al.16
and in ours. This could represent an additional confounding factor.
In conclusion, despite the limitations of this study, our findings
provide convergent evidence that the dysregulation of the
ubiquitin–proteasome system is involved in MDD response
treatment mechanisms. Independent replications are needed to
better understand the role of this system in psychiatric disorders.
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